ACP treatment guideline for antidepressants

January 2009
Neurology Alert;Jan2009 Pharmacology Watch, p2
The article reports on the practice guideline issued by the American College of Physicians for the use of antidepressants to treat depressive disorders. The guideline encompasses the use of newer second-generation antidepressants, including Selective Serotonin Reuptake Inhibitors (SSRI) and Serotonin and Norepinephrine Reuptake Inhibitors (SNRI). The guideline group concluded that there were no significant differences between the drugs with regard to efficacy after reviewing 203 clinical trials.


Related Articles

  • Escitalopram.  // AHFS Consumer Medication Information;Sep2020, p1 

    Escitalopram is used to treat depression and generalized anxiety disorder (GAD; excessive worry and tension that disrupts daily life and lasts for 6 months or longer). Escitalopram is in a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs). It works by increasing the...

  • Safety and Efficacy of s-Citalopram in Patients with Co-Morbid Major Depression and Diabetes Mellitus. Amsterdam, Jay D.; Shults, Justine; Rutherford, Nancy; Schwartz, Stanley // Neuropsychobiology;2006, Vol. 54 Issue 4, p208 

    Objective: The presence of co-morbid depressive symptoms may have a negative impact on the management of diabetes mellitus. Moreover, some antidepressants may adversely affect glycemic control. Selective serotonin reuptake inhibitors (SSRIs) may improve glycemic control and may be beneficial for...

  • The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature.  // NAPPP Monthly Newsletter;Oct2016, Vol. 11 Issue 10, p8 

    The article presents a study which examined the safety, tolerability, and risks related to the use of newer generation of antidepressant drugs (AD) for the treatment of major depressive disorders. Among the drugs are serotonin noradrenaline reuptake inhibitors, bupropion, and mirtazapine. Also...

  • Levomilnacipran.  // AHFS Consumer Medication Information;Sep2020, p1 

    Levomilnacipran is used to treat depression. Levomilnacipran is in a class of medications called selective serotonin and norepinephrine reuptake inhibitors (SNRIs). It works by increasing the amount of serotonin and norepinephrine, natural substances in the brain that helps maintain mental balance.

  • Clinical Characteristics as Predictors of Response to Fluvoxamine, Paroxetine and Milnacipran in Patients with Depression. Morishita, Shigeru; Arita, Seizabur // Current Psychiatry Reviews;2005, Vol. 1 Issue 3, p319 

    The advent of the selective serotonin reuptake inhibitors (SSRIs) and the dual serotonin noradrenaline reuptake inhibitors (SNRIs) has been welcomed by patients, largely owing to their superior tolerability profile as compared to older antidepressants. However, individual SSRIs and SNRIs do not...

  • Intermittent and continuous swim stress-induced behavioral depression: sensitivity to norepinephrine- and serotonin-selective antidepressants. Drugan, Robert C.; Macomber, Heather; Warner, Timothy // Psychopharmacology;Oct2010, Vol. 212 Issue 1, p85 

    Intermittent swim stress (ISS) produces deficits in swim escape learning and increases immobility in the forced swim test (FST). A previous attempt to reverse this immobility with the selective serotonin reuptake inhibitor (SSRI), fluoxetine (FLX), was unsuccessful, but the sensitivity of this...

  • SNRIs: The Latest Therapy to Emerge From Research on Depression. Delgado, Pedro L. // Behavioral Health Management;Jan/Feb2004, Vol. 24 Issue 1, pS1 

    Discusses the use of serotonin and norepinephrine reuptake inhibitors for the treatment of depression. Research on the biologic basis of depression; Pathophysiology of depression; Effect of neurotransmitters neropinepherine and serotonin on brain tissues.

  • The Role of Bupropion in the Management of Major Depressive Disorder. Ha, Khanh; Tawadros, Yousif; IsHak, Waguih William // Clinical Medicine Reviews in Therapeutics;2011, Vol. 3, p155 

    Bupropion is an antidepressant of the aminoketone class that is chemically unrelated to any other known antidepressant agent. In the treatment of major depressive disorder (MDD), bupropion has shown comparable therapeutic efficacy to selective serotonin reuptake inhibitors (SSRIs),...

  • Onset and Early Behavioral Effects of Pharmacologically Different Antidepressants and Placebo in Depression. Katz, Martin M.; Tekell, Janet L.; Bowden, Charles L.; Brannan, Steve; Houston, John P.; Berman, Nancy; Frazer, Alan // Neuropsychopharmacology;Mar2004, Vol. 29 Issue 3, p566 

    This study was aimed at resolving the time course of clinical action of antidepressants (ADs) and the type of early behavioral changes that precede recovery in treatment-responsive depressed patients. The first goal was to identify, during the first 2 weeks of treatment, the onset of clinical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics